<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587054</url>
  </required_header>
  <id_info>
    <org_study_id>01-070</org_study_id>
    <secondary_id>CA23766</secondary_id>
    <secondary_id>CA33049</secondary_id>
    <nct_id>NCT00587054</nct_id>
  </id_info>
  <brief_title>Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders</brief_title>
  <official_title>Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (&gt;18 Years) With Lymphohematopoietic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This is a phase II, single-center study to evaluate the efficacy of a novel cytoreductive
      regimen followed by CD34+E- selected T cell depleted allogeneic stem cell (or soybean
      agglutinated and E-rosetted BM) transplant as treatment for patients with acute and chronic
      leukemias, lymphoma and myelodysplstic syndrome/PNH. The impact of the change in conditioning
      regimen and use of CD34-selected T cell depleted PBSCs on transplanted related morbidity and
      mortality and disease free survival will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is: (1) to try to kill any cancer or precancer cells that are in
      your body, and to reduce the side effects of a transplant, which we have seen in our previous
      studies, (2) to see if this treatment with a new recipe of radiation and chemotherapy can
      suppress your immune system enough for the stem cells to 'take' and grow, (3) to see if the
      specially prepared stem cells can grow in you without a problem called graft-versus-host
      disease (GvHD) occurring.

      One of the major side effects of any stem cell transplant is a condition known as graft vs.
      host disease or GVHD. GVHD is an immune reaction caused by certain cells from the
      transplanted stem cells called T-lymphocytes (or T-cells). The T-cells from your donor may
      see your organs as foreign and attack them. New ways to remove the T-cells from the stem
      cells before the transplant are being used to try and prevent GVHD. In some studies, the
      removal of T-cells from the stem cells has been successful for many patients in preventing
      both short-term (acute) and long-term (chronic) forms of GVHD. However, the removal of
      T-cells may increase the chance that the new bone marrow developing from the stem cells will
      be rejected or will not function well. Rejection of the transplant means that some of your
      own cells have survived the chemo and radiation therapy, and are attacking the new bone
      marrow cells. This condition can be lifethreatening because of an increased risk of
      infections and bleeding and would require your getting more treatment and additional stem
      cells. Studies like this one are designed to find better ways to avoid GVHD without
      increasing the risk of other problems such as graft rejection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival of Transplant Patients</measure>
    <time_frame>up to 6 years</time_frame>
    <description>Calculate the median overall survival of transplant patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Allogeneic Stem Cell Transplant</condition>
  <condition>Leukemia</condition>
  <condition>Non-Hodgkins</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Transplant Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant</intervention_name>
    <description>Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.
Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines.</description>
    <arm_group_label>Transplant Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven acute or chronic leukemia, non Hodgkins and lymphoblastic
             lymphoma or myelodysplastic syndrome

          -  HLA 6/6 or 5/6 antigen matched related or unrelated donor

          -  creatinine = normal or if not, CrCl &gt; 60 ml/min/1.73ml

          -  total bilirubin &lt; 2.5, AST &lt; 2xnl, cardiac function &gt; 50%

          -  pulmonary function - asymptomatic or if not DLCO &gt; %50% (corrected for Hgb)

          -  Karnofsky performance status &gt; 70%

          -  negative pregnancy test (where applicable)

          -  signed informed consent of patient and donor.

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  unwillingness to comply with protocol treatment or follow-up

          -  uncontrolled infection

          -  HIV or HTLV positivity

          -  active CNS/skin disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Jakubowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering web site</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>non-Hodgkins</keyword>
  <keyword>lymphoblastic lymphoma</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>paroxysmal nocturnal hemoglobinuria (PNH)</keyword>
  <keyword>cytoreductive regimen</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transplant Patients</title>
          <description>Adult Patients (&gt;18 years) with Lymphohematopoietic Disorders will receive Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient not treated</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transplant Patients</title>
          <description>Adult Patients (&gt;18 years) with Lymphohematopoietic Disorders will receive Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival of Transplant Patients</title>
        <description>Calculate the median overall survival of transplant patients</description>
        <time_frame>up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transplant Patients</title>
            <description>Adult Patients (&gt;18 years) with Lymphohematopoietic Disorders will receive Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival of Transplant Patients</title>
          <description>Calculate the median overall survival of transplant patients</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727.5" lower_limit="12" upper_limit="2231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transplant Patients</title>
          <description>Adult Patients (&gt;18 years) with Lymphohematopoietic Disorders will receive Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-double vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms, other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection unknown absolut neutriphil counts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="117" subjects_affected="117" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="125" subjects_affected="125" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="125" subjects_affected="125" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="123" subjects_affected="123" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="124" subjects_affected="124" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ann Jakubowski</name_or_title>
      <organization>Memorial Sloan-Kettering Cancer Center</organization>
      <phone>212-639-5013</phone>
      <email>jakubowa@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

